• Exact Sciences (Marlborough, Massachusetts) said that improvements to its technology demonstrated sensitivity in excess of 80% for detecting colorectal cancer in a recent research study. The blinded study was designed to test the efficacy of technological advances to enhance colorectal cancer detection in stool. The study results have been submitted for presentation at the major annual meeting of gastroenterologists, Digestive Disease Week, which will be held in May. The results also are being submitted for publication. Exact Sciences uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of Exact Sciences technologies are being offered in a commercial testing service, PreGen-Plus, developed by Laboratory Corp. of America Holdings (Burlington, North Carolina). PreGen-Plus is used for screening for colorectal cancer in the average-risk population.

No Comments